drugset / Trial / NCT06528314
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Timeline
- Start
- 2024-09-04
- Primary completion
- 2030-02
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efruxifermin | Protein / enzyme biologic | 50 mg | Subcutaneous |